These nano-PROTACs can sequentially respond to extracellular matrix metalloproteinase-2 (MMP-2), acidic intracellular environments (pH < 6.2), and the reductive tumor microenvironment (GSH) to release the active PROTACs. This evidence concerns the gene MMP2 and neoplasm.